Sino Biopharma spends $951m to acquire China-based LaNova Medicines
Pharmaceutical Technology
JULY 15, 2025
The net payment made by Sino to acquire LaNova will be approximately $500.9m, a figure that excludes the estimated cash and bank deposits, according to a company document outlining the terms of the transaction. At the time, Sino spent 142 million yuan ($19.80m) to initiate its ownership involvement with the biotech.
Let's personalize your content